🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,522 results for “solution” Clear

  1. -, -, ERYTHROPOIETIN , DANAZOL , VAY736, -, ENTECAVIR , Placebo to VAY736 150 mg/1 mL concentrate for solution for infusion, -, -

    Novartis Pharmaceuticals

    warm autoimmune haemolytic anaemia (wAIHA)

    phase 3 small molecule active

    1 trial

  2. -, -, PACLITAXEL , DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-2870, MK-2870, DOXORUBICIN , CAPECITABINE , PACLITAXEL ALBUMIN-BOUND, DEXAMETHASONE , PARACETAMOL

    Merck Sharp and Dohme

    Hormone receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  3. -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -, CAPECITABINE , PARACETAMOL , MK-2870, DEXAMETHASONE

    Merck Sharp and Dohme

    Triple negative breast cancer.

    phase 3 small molecule active

    1 trial

  4. -, MVASI 25 mg/mL concentrate for solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, MK-2870, Avastin 25 mg/ml concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion.

    Merck Sharp and Dohme

    Ovarian cancer

    phase 3 small molecule active

    1 trial

  5. -, PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion., MK-2870, MVASI 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , MVASI 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., CISPLATIN

    Merck Sharp and Dohme

    Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1

    phase 3 small molecule active

    1 trial

  6. -, PARACETAMOL , MK-2870, PACLITAXEL , -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -, CARBOPLATIN , PACLITAXEL ALBUMIN-BOUND, DEXAMETHASONE

    Merck Sharp and Dohme

    Participants with treatment-naïve metastatic squamous Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  7. -, Placebo to ianalumab 150 mg/1 mL concentrate for solution for infusion, -, ENTECAVIR , -, ELTROMBOPAG, -, ELTROMBOPAG, ELTROMBOPAG, VAY736, -, ELTROMBOPAG

    Novartis Pharmaceuticals

    Primary immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  8. 0.05% Voclosporin Ophthalmic Solution (VOS)

    Aurinia Pharmaceuticals

    Dry Eye Syndrome

    phase 3 small molecule completed

    1 trial

  9. 0.9 % w/v Sodium Chloride Injection, Reblozyl 25 mg powder for solution for injection, Reblozyl 75 mg powder for solution for injection

    Celgene Europe Limited

    Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF)

    phase 3 small molecule active

    1 trial

  10. 0.9% (w/v) sodium chloride with 5 mM phosphate buffered solution, Zilebesiran

    Alnylam Netherlands B.V.

    High cardiovascular risk, Established cardiovascular disease, Hypertension

    phase 3 small molecule active

    1 trial

  11. 0.9% Sodium Chloride Solution, Glenzocimab

    Pari Pharma GmbH

    Acute ischemic stroke

    phase 3 small molecule active

    1 trial

  12. 0.9% Sodium Chloride for Injection, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion., JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  13. 0.9% Sodium chloride, Amvuttra 25 mg solution for injection in pre-filled syringe

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  14. 0.9% w/v sodium chloride solution for intravenous infusion, Panzyga 100 mg/ml Infusionslösung

    Maze Therapeutics

    Pediatric acute-onset neuropsychiatric syndrome (PANS)

    phase 3 small molecule active

    1 trial

  15. 25% AgNO3 solution followed by 5% NaF

    The University of Hong Kong

    Early Childhood Caries

    phase 3 small molecule completed

    1 trial

  16. 5% Dextrose injection; Solution for injection/infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., 0.9% Sodium Chloride injection; Solution for injection/infusion

    Bristol-Myers Squibb Australia Pty Ltd

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  17. 5-FU medac 50 mg/ml, Injektionslösung, Tecentriq 1 200 mg concentrate for solution for infusion, Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, Oxaliplatin medac 5 mg/ml concentrate for solution for infusion

    The George Institute

    locally advanced resectable adenocarcinoma of the oesophagogastric junction or the stomach

    phase 3 small molecule active

    1 trial

  18. 64Cu(II)Cl2 solution for injection

    A.C.O.M. - Advanced Center Oncology

    Cancer on the prostatic bed

    phase 3 small molecule active

    1 trial

  19. 64Cu(II)Cl2 solution for injection, Fluorocolina (18F) Curium Italy 225 MBq/mL soluzione iniettabile

    A.C.O.M. - Advanced Center Oncology

    Prostate cancer at risk of developing metastatic lesions

    phase 3 small molecule active

    1 trial

  20. A matching sterile product (Placebo Ophthalmic Solution) will be provided using the same excipient formulation as the active K-321 product., Ripasudil

    The George Institute

    Fuchs Endothelial Corneal Dystrophy

    phase 3 small molecule active

    1 trial

  21. A placebo matching Mepolizumab, Nucala 100 mg solution for injection in pre-filled syringe, A placebo matching Depemokimab, GSK3511294, Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection, Nucala 100 mg solution for injection in pre-filled syringe, Fasenra 30 mg solution for injection in pre-filled syringe

    GlaxoSmithKline

    Severe asthma with an eosinophilic phenotype

    phase 3 small molecule active

    1 trial

  22. A-101 Solution

    Aclaris Therapeutics

    Seborrheic Keratosis

    phase 3 small molecule completed

    3 trials

  23. ABBV-066 / Risankizumab, ABBV-066, Entyvio 300 mg powder for concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  24. ABBV-066 / Risankizumab, Risankizumab, Matching Placebo for 90 mg solution for injection, ABBV-066, Matching placebo for 180 mg solution for injection

    AbbVie Deutschland GmbH & Co. KG

    Crohn's disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources